Generated by AI
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapeutics. Kamada Ltd. develops, manufactures, and markets a portfolio of marketed products for rare and serious conditions, with treatments used in areas such as lung disease, immunology, infectious disease prophylaxis, and critical care. The company’s commercial offering includes proprietary plasma-derived therapies and a distribution segment that markets additional biopharmaceutical products in selected international markets. Kamada Ltd. also operates manufacturing capabilities centered on plasma protein purification and sterile production, supporting its vertically integrated business model. Its products are sold through partners, distributors, hospitals, pharmacies, and healthcare organizations across multiple countries, making the company a specialized supplier within the global plasma therapeutics market.
Website2 Holzman Street
Rehovot, 7670402
Israel
The latest articles about KMDA.
Kamada Ltd (KMDA) posted record nine-month revenue of $152.2 million and lifted its 2026 outlook to $205-$208 million, with management projecting another year of double-digit growth in 2027.
Summary of Mar 11's posts. Generated by AI.
No summary yet.
Summary of Dec 6's posts. Generated by AI.
Summary of Aug 7's posts. Generated by AI.
Summary of Dec 6's posts. Generated by AI.
Investors talking about KMDA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.